Comparative Pharmacology
Head-to-head clinical analysis: ALPHACAINE versus DURANEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHACAINE versus DURANEST.
ALPHACAINE vs DURANEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Etonidate is an ultrashort-acting nonbarbiturate hypnotic agent that produces anesthesia by enhancing GABA-mediated chloride conductance at GABA-A receptors, leading to central nervous system depression.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
2-10 mL of a 1-2% solution, subarachnoid injection, single dose only.
None Documented
None Documented
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Terminal elimination half-life is 4.5 hours (range 3-6 hours). Clinical context: Prolonged in severe hepatic impairment but not significantly in renal impairment.
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug. Biliary/fecal elimination is minimal.
Category C
Category C
Local Anesthetic
Local Anesthetic